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Abstract
Background: Prostatic carcinoma is the second most common cause of cancer-related deaths in
males in the West. Approximately 20% of patients present with metastatic disease. We describe
the case of a patient with metastatic prostate cancer to the bowel presenting clinically and
radiologically as a primary caecal cancer.
Case presentation: A 72 year-old man presented with abdominal discomfort and a clinically
palpable caecal mass and a firm nodule on his thigh, the latter behaving clinically and radiologically
as a lipoma. Computed tomographic (CT) scan showed a luminally protuberant caecal mass with
regional nodal involvement. The patient was being treated (Zoladex®) for prostatic cancer
diagnosed 6 years previously and was known to have bony metastases. On admission his PSA was
245.4 nmol/ml. The patient underwent a right hemicolectomy. Histology showed a poorly
differentiated adenocarcinoma which was PSA positive, confirming metastatic prostatic
adenocarcinoma to the caecum. The patient underwent adjuvant chemotherapy and is free from
recurrence a year later.
Conclusion:  Metastasis of prostatic carcinoma to the bowel is a very rare occurrence and
presents a challenging diagnosis. The diagnosis is supported by immunohistochemistry for PSA. The
treatment for metastatic prostate cancer is mainly palliative.
Background
Prostatic carcinoma is the second most common cause of
cancer related deaths in males in the West [1]. Approxi-
mately 20% of patients present with metastatic disease
but colo-rectal involvement is rare[2]. We describe the
case of a patient with metastatic prostate cancer to the
bowel presenting as primary caecal cancer.
Case presentation
A 72-year-old man presented with abdominal discomfort
with small amount of bleeding per rectum and a clinically
palpable lump in the right iliac fossa. He also had a large,
firm, mobile lump on his left thigh.
He had been treated six years previously for prostatic car-
cinoma which was Gleason's grade 3+3= 6. Bony metas-
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tases had been diagnosed recently. He was on Zoladex®
injections.
Clinical examination showed a 6 cm hard, mobile, non-
tender mass in his right iliac fossa. Digital rectal examina-
tion was unremarkable. Rigid sigmoidoscopy revealed
radiation proctitis, which would explain his bleeding per
rectum. CT scan of abdomen showed a caecal tumour
with regional lymphadenopathy and vertebral metastasis
(Figure 1). A non-palpable left iliac mass was identified:
this was defined as internal iliac nodes lymphadenopathy,
associated with partial obstruction of the left ureter (the
possibility of prostatic metastasis to these nodes was con-
sidered). A fatty mass lesion was identified in the left
thigh, the CT appearances of which were that of a simple
lipoma; this has remained unchanged on subsequent CT
scans. Bone scan confirmed bony metastasis in the 12th
thoracic and 1st lumbar vertebrae and rib cage. In 2003,
there was a gradual rise in his PSA levels which had gone
upto 233 nmol/ml. Zoladex® injections were then started
and his PSA levels fell to 6.3 nmol/ml by January 2004.
This however had gradually risen again to 254.4 nmol/ml
on admission, inspite of being on Zoladex®.
The patient underwent a right hemicolectomy for what
appeared to be an obvious locally advanced luminally
protuberant caecal carcinoma with mesenteric lymph
nodal involvement. Histopathological examination of the
specimen showed a poorly differentiated adenocarcinoma
of the caecum extending throughout the whole bowel
wall and breaching the serosa with metastatic involve-
ment of 5 of 15 paracolic lymph nodes (Figure 2). The
possibility of prostatic metastasis was considered and con-
firmed on immunohistochemical staining for PSA (Figure
2) and, given this, stains for CK7, CK20 and CDX2 immu-
noprofile were considered unnecessary. The final histo-
logical diagnosis was of a metastatic prostatic
adenocarcinoma to the caecum. The patient underwent
adjuvant chemotherapy with Docetaxel and Paclitaxel and
is free from recurrence a year later.
Discussion
Progression of prostate cancer occurs either by direct
extension or metastasis through haematogenous or lym-
phatic routes. The most commonly involved organs are
the seminal vesicles, base of the bladder, bones (mainly
axial skeleton) and lymph nodes[1]. Widespread visceral
involvement is quite rare. Some unusual sites of spread
have been described in literature as the parotid gland[3],
oesophagus[4], vocal cords[5], larynx[6], lung &bron-
chus[7], stomach[8], liver[9], skin[10], umbilicus [11],
sphenoid sinus[12], cranium[13], meninges[14], tes-
tes[15], penis[16], breast[17], mediastinum[18], thymus
[19], orbit[20], uveal tract[21], brain[22], cerebellum[23]
and bones[24]. Rectal seeding on needle biopsy[25] and
direct involvement occasionally occurs [26], but distant
metastasis to the bowel is quite rare (prevalence 1–4% in
autopsy series)[27]. So far only three accounts of metasta-
sis to the distant bowel have been recorded, one involving
the small bowel[27] and the other two involving the rec-
tosigmoid[28,29].
It is important to distinguish primary from metastatic
colorectal lesions, especially in the presence of a previous
history of cancer at another site, in order to facilitate
appropriate management. This is best achieved by defin-
ing the tumour type on histopathologic grounds and, in
this instance, by immunohistochemical staining for
PSA[17,30]. The treatment of primary colonic adenocarci-
nomas is potentially curative with a combination of sur-
gery and chemo-irradiation; treatment of colonic
metastasis depends on the primary site and might not be
'curative'. The treatment of metastatic disease from the
prostate is purely palliative; hormonal treatment repre-
sents the standard[31], although this can be combined
with debulking surgery to reduce the tumour load where
feasible. However, the impact of debulking surgery on
patient survival is not known. Metastatic prostate cancer
has poor prognosis and survival rates range from 1 to 3
years[8].
The response of prostatic carcinoma to oestrogen therapy
has been well established[32] but patients often become
refractory after prolonged treatment. Options for hor-
mone-refractory prostate cancer include secondary hor-
monal treatment (anti-androgens), radiotherapy and
cytotoxic chemotherapy. The metastatic component, as
described in our case, can be managed with debulking sur-
gery and may well need adjuvant chemotherapy or sec-
ondary hormonal treatment to achieve reasonable
regression of disease.
Conclusion
Metastasis of prostatic carcinoma to the bowel is a very
rare occurrence and presents a challenging diagnosis. The
mainstay of diagnosis is histopathology supported by
immunohistochemistry for PSA.
Palliative treatment remains the mainstay of therapy for
metastatic prostate cancer and hormonal therapy repre-
sents the standard with debulking surgery where feasible.
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a) Imaging shows a well defined caecal tumour (arrow) with evidence of vertebral metastasis (arrowhead) Figure 1
a) Imaging shows a well defined caecal tumour (arrow) with evidence of vertebral metastasis (arrowhead). b) The tumour is 
irregular in outline (arrow) and is closely approximated to the anterior abdominal wall.
a) Histology shows a well defined intraluminal, protuberant tumour invading the submucosa Figure 2
a) Histology shows a well defined intraluminal, protuberant tumour invading the submucosa. This invasive tumour extends to 
pericolonic fibroadipose tissue. b) This tumour is positive with PSA, confirming its metastatic origin from a primary prostatic 
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